TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06150833: Evaluating the Safety, Effectiveness, and Pharmacokinetics of Boya Intravenous Immune Globulin in Patients With Primary Immune Deficiency.

Sponsor: Azidus Brasil · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT06150833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06150833 Rescue Dossier →